European Lung Cancer Congress | Conference

Dr. Reck on the Rationale of the Impower150 Study

April 12th 2019

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

Dr. Paz-Ares on Entrectinib in NTRK Fusion-Positive NSCLC

April 12th 2019

Luis G. Paz-Ares, MD, PhD, chief physician at the Hospital Universitario Doce De Octubre, discusses an integrated analysis of patients with NTRK fusion–positive non–small-cell lung cancer enrolled in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, which evaluated the safety and efficacy of entrectinib in patients with solid tumors.

Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

April 12th 2019

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

PD-L1 Expression Does Not Impact QoL With Durvalumab in NSCLC

April 11th 2019

Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.

Subsequent Immunotherapy in Control Arm Confounds Frontline Durvalumab Data in NSCLC

April 11th 2019

The initial overall survival analysis of the phase III MYSTIC trial of first-line durvalumab (Imfinzi) alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer, may have been confounded by high rates of post-study immunotherapy given in the control arm.

Dr. Passaro on Clinical Factors Linked With Improved Outcomes to ALK Inhibitors in NSCLC

April 11th 2019

Antonio Passaro, MD, PhD, of the Division of Thoracic Oncology, European Institute of Oncology, discusses a study that sought to determine the factors that have an impact on 5-year survival among patients treated for metastatic non–small cell lung cancer using ALK TKIs.

Updated Data Continue to Showcase Efficacy of Larotrectinib, Entrectinib in NSCLC

April 11th 2019

Larotrectinib showcased an overall response rate of 71% in patients with non–small cell lung cancer harboring NTRK gene fusions.

Dr. Horn on Monitoring Response and Resistance to Ensartinib in ALK+ NSCLC

April 11th 2019

Leora Horn, MD, MSc, associate professor of cancer research, Vanderbilt University Medical Center, discusses the use of circulating tumor DNA analysis as a means to monitor response to, as well as resistance to, ensartinib in patients with ALK–positive non–small cell lung cancer.

Dr. Ramalingam on the Significance of the FLAURA Trial in NSCLC

April 16th 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the significance of the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non

QoL Data Support Durvalumab Use in Locally Advanced NSCLC

April 14th 2018

Durvalumab treatment over 12 months had no negative effect on key symptoms of lung cancer, physical function, global health status, or quality of life in patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following concurrent chemoradiotherapy.

Dr. Yang on Resistance Mechanisms from Osimertinib in NSCLC

April 14th 2018

James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses resistance mechanisms that develop from treatment with osimertinib (Tagrisso) and other EGFR tyrosine kinase inhibitors (TKIs). Yang discussed this in an interview during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.

Post-Progression Data Establishes Osimertinib as Frontline Standard of Care for EGFR-Mutant NSCLC

April 14th 2018

First-line treatment with osimertinib resulted in a clinically meaningful delay in time from randomization to second progression on subsequent treatment or death, establishing the agent as a new standard of care in the frontline setting for patients with EGFR-mutant non–small cell lung cancer.

Dr. Besse Discusses Challenges Facing Stage IV NSCLC

April 13th 2018

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non

Dr. Reck on the Rationale of the IMpower150 Trial in NSCLC

April 13th 2018

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non

Necitumumab/Abemaciclib Combo Fails in Stage IV NSCLC

April 13th 2018

A phase Ib study of necitumumab in combination with abemaciclib failed to meaningfully improve outcomes in patients with stage IV non–small cell lung cancer.

Osimertinib Prevents CNS Progression in Advanced NSCLC in a Real-World Setting

April 13th 2018

Patients with advanced non–small cell lung cancer and baseline central nervous system metastasis showed control of their CNS metastasis after receiving osimertinib in a real-world clinical setting.

Nivolumab Benefit Unresolved in Unresectable or Recurrent Thymic Cancer

April 13th 2018

Researchers from Japan recommended against further development of nivolumab for patients with previously treated unresectable or recurrent thymic carcinoma based on their findings from the phase II PRIMER study.

Frontline Osimertinib Controls Symptoms for Patients With EGFR-Mutated NSCLC

April 13th 2018

Frontline treatment with osimertinib led to similar improvements in quality of life, including a clinically meaningful improvement in cough, compared with a standard of care EGFR TKIs for patients with advanced EGFR-mutant non–small cell lung cancer.

Dr. Perol Discusses Results of the ALEX Trial in ALK+ NSCLC

April 12th 2018

Maurice Perol, MD, medical oncologist, Centre Leon Berard, discusses the results of the ALEX trial in ALK-positive non–small cell lung cancer.

Dr. Garon Discusses the CheckMate-384 Study in NSCLC

April 12th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.